By seamlessly connecting scientific discoveries with patient care, we integrate world-class research infrastructure, scientific expertise, medical knowledge, and strategic partnerships with industry leaders both nationally and internationally. This innovative approach positions CBmed at the forefront of precision medicine, transforming therapeutic strategies beyond traditional one-size-fits-all models.

Our core strength lies in combining state-of-the-art research infrastructure with strong connections to leading biobanks, including Europe’s largest, Biobank Graz, and the European Biobank Network BBMRI-ERIC. These collaborations enable us to identify and validate new biomarkers and advance translational research for real-world clinical applications.

CBmed’s cutting-edge technologies offer comprehensive, multi-platform analyses for a deeper understanding of biomarker research. By integrating multi-omics data from various sources, we create synergies that directly contribute to clinical decision support.

Our expertise in multi-omics research, coupled with Total Quality Management and advanced Lab Information and Management Systems (LIMS), ensures precise and rigorous documentation of all lab processes, from sample tracking to final reporting. This commitment to accuracy, personalization, and quality reflects our dedication to advancing healthcare research.

CBmed’s revolutionary ex-vivo compound screening platform, which uses patient-derived tumor spheroids, allows us to assess the effectiveness of therapeutic agents for individual patients. This approach not only enables personalized treatment strategies but also accelerates drug development for our industry partners.

At CBmed, we are at the cutting edge of biomarker research, using our unique position and collaborations to drive innovations that have a lasting impact on patient care and cure.